Journal articleHuman
Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Nov 19. Liu Y, Pan Y, Hu Z and 13 others.
Study type
Journal article
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published
2020 Nov 19
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19FemaleHumansLymphopeniaMaleMiddle AgedRetrospective StudiesSARS-CoV-2
Other papers on Thymosin α-1
Systematic review / meta-analysis · 2016
The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
Randomized controlled trial · 2013The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page